Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients

Transplant International

Volumn 21, Issue 4, 2008, Pages 346-352

  Park, Jae Berm ^a   Kwon, Choon Hyuck David ^a   Lee, Kwang Woong ^a   Choi, Gyu Seong ^a   Kim, Doo Jin ^a   Seo, Jeong Min ^a   Kim, Sung Joo ^a   Joh, Jae Won ^a   Lee, Suk Koo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

De novo HBV infection; Hepatitis B core antibody; Living donor liver transplantation; Pediatric; Prevention

Indexed keywords

EUVAX; HEPA BIG; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPAVAX; RECOMBINANT HEPATITIS B VACCINE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GRAFT REJECTION; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PRIORITY JOURNAL; VACCINATION;

EID: 40449094184     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00618.x     Document Type: Article

References (31)

1. 1 Park KS, Lee SY, Lee SG, et al. A study of markers of viral hepatitis in adults living in Daegu and Gyungbuk area. Korean J Gastroenterol 2003 ; 41: 473.
2. 2 Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997 ; 64: 1582.
3. 3 Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation‐associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997 ; 3: 105.
4. 4 Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997 ; 113: 1668.
5. 5 Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody‐positive donors in an area with high prevalence of anti‐HBc positivity in the donor population. Liver Transpl 2001 ; 7: 51.
6. 6 Roque‐Afonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti‐HBC positive donors. Gut 2002 ; 50: 95.
7. 7 Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(‐), HBcAb(+), HBIgM(‐) organ donors. Transplantation 1995 ; 59: 230.
8. 8 Segovia R, Sanchez‐Fueyo A, Rimola A, et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001 ; 7: 106.
9. 9 Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti‐HBc positive donors. Transplantation 1999 ; 68: 1058.
10. 10 Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002 ; 8: 556.
11. 11 Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody‐positive donors in living related liver transplants. Transplantation 1998 ; 65: 494.
12. 12 Chen YS, Wang CC, De Villa VH, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002 ; 16: 405.
13. 13 Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody‐positive donors in orthotopic liver transplantation. Arch Surg 2002 ; 137: 572.
14. 14 Suehiro T, Shimada M, Kishikawa K, et al. Prevention of hepatitis B virus infection from hepatitis B core antibody‐positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005 ; 25: 1169.
15. 15 Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long‐term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface‐antigen negative liver transplant recipients from hepatitis B core‐antibody‐positive donors. Clin Transplant 2006 ; 20: 369.
16. 16 Lee KW, Lee DS, Lee HH, et al. Prevention of de novo hepatitis B infection from HbcAb‐positive donors in living donor liver transplantation. Transplant Proc 2004 ; 36: 2311.
17. 17 Barcena MR, Garcia‐Hoz F, Vazquez RM, et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002 ; 97: 2398.
18. 18 Perrillo RP, Wright T, Rakela J, et al. A multicenter United States‐Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 ; 33: 424.
19. 19 Yen RD, Bonatti H, Mendez J, Aranda‐Michel J, Satyanarayana R, Dickson RC. Case report of lamivudine‐resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006 ; 6: 1077.
20. 20 Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003 ; 37: 1329.
21. 21 Lin CC, Chen CL, Concejero A, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007 ; 7: 195.
22. 22 Yi NJ, Suh KS, Cho JY, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007 ; 13: 451.
23. 23 Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 ; 329: 1842.
24. 24 McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996 ; 61: 1358.
25. 25 Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998 ; 27: 213.
26. 26 Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. Novel immunoassay for the detection of hepatitis B surface ‘escape’ mutants and its application in liver transplant recipients. J Med Virol 2001 ; 63: 210.
27. 27 Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998 ; 28: 555.
28. 28 Cooreman MP, Leroux‐Roels G, Paulij WP. Vaccine‐ and hepatitis B immune globulin‐induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001 ; 8: 237.
29. 29 Kwon CH, Suh KS, Yi NJ, et al. Long‐term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant 2006 ; 10: 479.
30. 30 Bienzle U, Gunther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease. Hepatology 2003 ; 38: 811.
31. 31 Rosenau J, Hooman N, Rifai K, et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B‐related disease: failure of humoral and cellular immune response. Transpl Int 2006 ; 19: 828.